Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2011 Financial Results on November 8, 2011
Date:11/1/2011

LYNBROOK, N.Y., Nov. 1, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EST on Tuesday, November 8, 2011 to report its third quarter 2011 financial results and provide a corporate update.

In order to participate in the conference call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.videonewswire.com/event.asp?id=83154.

A replay of the call will be available one hour after the end of the conference on November 8, 2011 until 9:00 a.m. EST on November 18, 2011. To access the replay, please dial 877-344-7529 (domestic) or 412-317-0088 (international) and reference the access code 10005920. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease which is currently in Phase 3 pivotal clinical trials, frozen shoulder (Adhesive Capsulitis) and cellulite. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
2. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
4. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2010 Financial Results on March 11, 2011
5. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
6. BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
7. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
8. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
9. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
10. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Diego, CA (PRWEB) , ... May 23, 2017 , ... ... matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter ... impact of biofilms is in the tens of billions of dollars per year, there ...
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm that partners with healthcare ... has opened an office in downtown Boston at 745 Atlantic Ave. , “We ... to generate evidence on the value they provide, not just to patients, but also ...
(Date:5/21/2017)... ... May 19, 2017 , ... ... educational conference of the American Association of Bioanalysts (AAB) and the College of ... Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory services and ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... Academic researchers with technologies ripe for commercialization, and who are affiliated with ... are encouraged to submit proposals. QED, now in its tenth round, is the ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):